Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 7/20 | 0.55 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.52 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNG | P07510 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
| ▸ | CHRND | Q07001 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492268 | 0.99 | TACR2 (0.57) | TACR2AVPR1AAVPR1BCHRNB2CHRNB4 | |
| SCHEMBL5494652 | 0.95 | TACR2 (0.53) | TACR2AVPR1AAVPR1BCHRNA1CHRNG | |
| SCHEMBL5491193 | 0.94 | TACR2 (0.55) | TACR2AVPR1AAVPR1BMMP1 | |
| SCHEMBL5496976 | 0.88 | TACR2 (0.54) | TACR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5489864 | 0.84 | CHRNA1 (0.48) | TACR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5493574 | 0.83 | CHRNA1 (0.47) | TACR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6407102 | 0.82 | F7 (0.52) | TACR2MMP1CTSB | |
| SCHEMBL6409719 | 0.81 | F7 (0.51) | TACR2MMP1CTSB | |
| SCHEMBL6411246 | 0.78 | MMP1 (0.54) | MMP1CTSB | |
| SCHEMBL5494642 | 0.78 | GAA (0.45) | TACR2CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | TACR2 2185/4885AVPR1A 2997/4885AVPR1B 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.